Tonix's Long COVID Drug Fails to Meet Midstage Trial Goal

Tonix Pharmaceuticals said on Tuesday its experimental drug failed to meet the primary goal in a midstage study for management of widespread muscle pain and tenderness associated with long COVID-19.
Reuters Health Information

source https://www.medscape.com/s/viewarticle/996097?src=rss

Comments

Popular posts from this blog

Student Nurses Who Refuse Vaccination Struggle to Complete Degrees

The Clinical Characteristics of Fractures in Pediatric Patients Exposed to Proton Pump Inhibitors